Biohaven Pharmaceutical Holding Company Ltd.

69.39-1.53-2.16%Vol 439.74K1Y Perf 92.18%
Apr 9th, 2021 16:00 DELAYED
BID66.01 ASK74.00
Open70.22 Previous Close70.92
Pre-Market- After-Market-
 - -  - -%
Target Price
102.40 
Analyst Rating
Strong Buy 1.25
Potential %
47.57 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
100/-54/-81 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
100/-46/-91 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
100/-48/-91 
Income Ranking
 —    -
Market Cap4.31B 
Earnings Rating
Sell
Price Range Ratio 52W %
54.46 
Earnings Date
6th May 2021

Today's Price Range

68.7770.50

52W Range

31.86100.77

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
1.66%
1 Month
-8.63%
3 Months
-19.05%
6 Months
-11.02%
1 Year
92.18%
3 Years
170.00%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
BHVN69.39-1.5300-2.16
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
ProfitabilityValueIndustryS&P 500US Markets
72.20
-2 196.10
-2 196.10
-
-
RevenueValueIndustryS&P 500US Markets
62.48M
0.97
-
-
Earnings HistoryEstimateReportedSurprise %
Q04 2020-2.89-3.62-25.26
Q03 2020-2.74-3.27-19.34
Q02 2020-2.78-2.558.27
Q01 2020-2.28-2.39-4.82
Q04 2019-1.96-2.85-45.41
Q03 2019-2.00-2.04-2.00
Q02 2019-1.90-2.35-23.68
Q01 2019-1.80-1.4121.67
Earnings Per EndEstimateRevision %Trend
3/2021 QR-2.96-8.82Negative
6/2021 QR-2.85-10.04Negative
12/2021 FY-10.70-13.47Negative
12/2022 FY-6.37-23.69Negative
Next Report Date6th May 2021
Estimated EPS Next Report-2.94
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume439.74K
Shares Outstanding62.04M
Trades Count7.24K
Dollar Volume51.29M
Avg. Volume662.09K
Avg. Weekly Volume705.30K
Avg. Monthly Volume806.24K
Avg. Quarterly Volume677.96K

Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) stock closed at 69.39 per share at the end of the most recent trading day (a -2.16% change compared to the prior day closing price) with a volume of 439.78K shares and market capitalization of 4.31B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 647 people. Biohaven Pharmaceutical Holding Company Ltd. CEO is Vlad Coric.

The one-year performance of Biohaven Pharmaceutical Holding Company Ltd. stock is 92.18%, while year-to-date (YTD) performance is -19.04%. BHVN stock has a five-year performance of %. Its 52-week range is between 31.86 and 100.77, which gives BHVN stock a 52-week price range ratio of 54.46%

Biohaven Pharmaceutical Holding Company Ltd. currently has a PE ratio of -5.20, a price-to-book (PB) ratio of 29.80, a price-to-sale (PS) ratio of 68.55, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -144.43%, a ROC of -751.37% and a ROE of 384.89%. The company’s profit margin is -%, its EBITDA margin is -2 196.10%, and its revenue ttm is $62.48 Million , which makes it $0.97 revenue per share.

Of the last four earnings reports from Biohaven Pharmaceutical Holding Company Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-2.94 for the next earnings report. Biohaven Pharmaceutical Holding Company Ltd.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Biohaven Pharmaceutical Holding Company Ltd. is Strong Buy (1.25), with a target price of $102.4, which is +47.57% compared to the current price. The earnings rating for Biohaven Pharmaceutical Holding Company Ltd. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biohaven Pharmaceutical Holding Company Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biohaven Pharmaceutical Holding Company Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 6.20, ATR14 : 5.01, CCI20 : -61.88, Chaikin Money Flow : -0.15, MACD : -1.14, Money Flow Index : 41.65, ROC : 2.57, RSI : 46.20, STOCH (14,3) : 38.49, STOCH RSI : 0.47, UO : 47.64, Williams %R : -61.51), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biohaven Pharmaceutical Holding Company Ltd. in the last 12-months were: Charles Conway (Option Excercise at a value of $0), Declan Doogan (Sold 600 000 shares of value $39 365 594 ), Elyse Stock (Option Excercise at a value of $957 511), Elyse Stock (Sold 36 966 shares of value $2 396 501 ), Gregory Hugh Bailey (Option Excercise at a value of $4 107 876), Gregory Hugh Bailey (Sold 850 000 shares of value $62 243 678 ), James Engelhart (Option Excercise at a value of $440 755), James Engelhart (Sold 73 725 shares of value $4 872 601 ), John Tilton (Option Excercise at a value of $483 080), John Tilton (Sold 52 000 shares of value $3 504 000 ), John W. Childs (Buy at a value of $5 966 821), Kimberly Gentile (Option Excercise at a value of $358 315), Kimberly Gentile (Sold 48 500 shares of value $3 549 059 ), Robert Berman (Option Excercise at a value of $201 000), Robert Berman (Sold 125 000 shares of value $9 406 626 ), Vlad Coric (Option Excercise at a value of $0), William B.J. Jones (Option Excercise at a value of $1 521 600), William B.J. Jones (Sold 30 000 shares of value $2 286 676 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
7 (87.50 %)
7 (77.78 %)
7 (77.78 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (12.50 %)
2 (22.22 %)
2 (22.22 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.25
Strong Buy
1.44
Strong Buy
1.44

Biohaven Pharmaceutical Holding Company Ltd.

Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV3000-301, BHV3000-302, BHV3000-303, and others.

CEO: Vlad Coric

Telephone: +1 203 404-0410

Address: C/o Biohaven Pharmaceuticals, Inc., New Haven 06510, CT, US

Number of employees: 647

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

58%42%

Bearish Bullish

55%45%

Bearish Bullish

64%36%

News

Stocktwits